Abeona Stock Moves Higher After MPS IIIA Gene Therapy Shows Increase In Brain VolumeBenzinga • 07/26/21
Abeona Therapeutics Announces New MRI Data Showing Increased Brain Volume in Young Patients with Sanfilippo Syndrome Type A (MPS IIIA) After Treatment with ABO-102 Gene TherapyGlobeNewsWire • 07/26/21
Abeona Therapeutics Activates Second Clinical Trial Site in EB-101 Pivotal Phase 3 VIITAL™ Study for Recessive Dystrophic Epidermolysis BullosaGlobeNewsWire • 07/23/21
Abeona Unveils Additional Data From Gene Therapy Trial For Rare Connective Tissue DisorderBenzinga • 07/07/21
Abeona Therapeutics Announces Updated EB-101 Phase 1/2a Clinical Results in Recessive Dystrophic Epidermolysis Bullosa at the Society for Pediatric Dermatology 46th Annual MeetingGlobeNewsWire • 07/07/21
Abeona Therapeutics Inc. (ABEO) CEO Michael Amoroso on Q1 2021 Results - Earnings Call TranscriptSeeking Alpha • 05/25/21
Abeona Therapeutics Announces Presentation on New Preclinical Data Supporting the Potential of Cre-Mediated Dual AAV Vector Technology to Enable Delivery of Large Genes Targeted for Treatment of Stargardt Disease at ARVO 2021 Annual MeetingGlobeNewsWire • 04/20/21
Abeona Therapeutics Appoints Two Industry Leaders as New Independent Members to Its Board of DirectorsGlobeNewsWire • 04/19/21
Abeona Therapeutics Inc. (ABEO) CEO Michael Amoroso on Q4 2020 Results - Earnings Call TranscriptSeeking Alpha • 03/25/21
Abeona Therapeutics Announces Appointment of Two New Independent Members to its Board of DirectorsGlobeNewsWire • 03/25/21
Abeona Therapeutics (ABEO) Reports Q4 Loss, Lags Revenue EstimatesZacks Investment Research • 03/24/21
Abeona Therapeutics Announces 2020 Financial Results and Recent Operational ProgressGlobeNewsWire • 03/24/21
SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Abeona Therapeutics Inc. for Potential Breaches Of Fiduciary Duty By Its Board of DirectorsPRNewsWire • 03/23/21
Abeona Therapeutics Announces Appointment of Michael Amoroso as Chief Executive OfficerGlobeNewsWire • 03/22/21
Abeona Therapeutics to Present at the 10th Annual SVB Leerink Global Healthcare ConferenceGlobeNewsWire • 02/22/21
New Positive Phase 1/2 Interim Data Presented at WORLDSymposium™ Shows Neurocognitive Development of Young MPS IIIA Patients Preserved up to Three Years Following Treatment with Abeona's ABO-102 Gene TherapyGlobeNewsWire • 02/12/21